GlassScriptPhysician profile
Fatima Jalil
NPI 1487086625
$1,606.01
in general payments reported to CMS, 2019-2025
12 companies · $917 in 2025
The $917 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.46 · 2021: $200 · 2022: $89.05 · 2023: $186 · 2024: $184 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,221 · Gift: $59.40 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,220.68 |
| Gift | $59.40 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $528.41 | 2021-2025 | Ozempic |
| Abbott Laboratories | $393.24 | 2022-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $334.64 | 2021-2025 | Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.19 | 2024-2025 | Jardiance |
| Amgen INC. | $62.27 | 2025 | Tepezza |
| Mannkind Corporation | $59.40 | 2023 | Afrezza |
| Insulet Corporation | $36.64 | 2025 | Omnipod |
| Abbvie INC. | $26.83 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.75 | 2025 | |
| Tandem Diabetes Care, INC. | $16.20 | 2019 | |
| Merck Sharp & Dohme LLC | $14.26 | 2019 | |
| Xeris Pharmaceuticals, INC. | $13.18 | 2024 | Recorlev |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fatima Jalil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.